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Description
FIELD
[0001] This disclosure relates to recombinant single-chain antibodies and methods of producing and using such an-
tibodies.
BACKGROUND
[0002] Genetic engineering approaches have allowed the production of recombinant antibodies having specific binding
specificities, specific domain structures, and other desirable properties. One type of genetically engineered antibody is
the single chain Fv fragment (scFv). Single chain Fv fragments are genetically engineered polypeptides that contain a
heavy chain variable region (VH) linked to a light chain variable region (VL) via a flexible peptide linker. Each VH and
VL domain contains three complementarity determining regions (CDRs). CDRs are short amino acid sequences that
vary greatly among antibody molecules, and thus, are responsible for generating the great diversity of antibody binding
specificity. The combination of the CDRs of the VH plus the CDRs of the VL determines the binding specificity of any
given antibody.
[0003] Single chain Fv fragments display the binding specificity and monovalent binding affinity of full-size antibodies
and provide the added benefit of relative ease of genetic manipulation and expression (because scFvs are encoded by
and expressed from a single coding sequence, rather than from separate coding sequences, as are full-size antibodies).
Single chain Fv fragments and other recombinant antibodies are used in a broad variety of applications, for example,
in medical diagnostic tests, in basic research; and as therapeutic antibody treatments for various diseases.
[0004] Intrabodies are genetically-engineered antibody molecules that are ectopically expressed within cells. Intra-
bodies can be used to visualize or to modulate the function of a target antigen within living cells. For example, the use
of intrabodies can induce a phenotypic knockout either by directly inhibiting the function of the targeted antigen or by
diverting the targeted antigen from its normal intracellular location (e.g., an intrabody can redirect its target antigen to
the degradation machinery). Intrabodies can also enhance or change the function of their target antigens. For protein
targets, intrabodies can be targeted to a specific post-translational modification or to a specific antigen conformation.
Moreover, an intrabody-induced phenotypic knockout can be confined to a specific cell compartment by targeting an
intrabody to the specific subcellular compartment using an addressing signal (e.g., a nuclear localization signal, a
mitochondrial localization signal, or an endoplasmic reticulum retention signal). Intrabodies can also modulate target
function by modifying the oligomeric structure of the target.
[0005] Because intrabody phenotypic knockout relies only on the binding capacity of the antibody molecule to its target,
it is not necessary to express within the cell a complete antibody molecule but only its binding site, which is entirely
located within the variable region (Fv). Given their advantages of small size and antigen specificity encompassed within
a single polypeptide chain, scFvs are the most common type of recombinant antibody fragment used for intracellular
antibody expression.
[0006] One serious limitation to the use of intrabodies is that most scFvs are not able to fold under the reducing
conditions of the cell cytosol and nucleus. Under such conditions the two conserved disulfide bridges of scFvs are
reduced, thereby destabilizing and inactivating the binding activity of many scFvs. In vitro, most scFvs cannot be renatured
under reducing conditions. Statistical analyses of scFv sequences have shown that fewer than 1% of the scFvs are
stable enough to be expressed and active in absence of disulfide bond formation. In addition, even if a scFv protein is
indeed stable enough in its reduced form to be expressed and active in vivo, other parameters such as protease sus-
ceptibility or folding kinetics may also influence the final in vivo fate of the intrabody and thus are critical for ultimate
intrabody expression and activity.
[0007] To obtain an active intrabody, current approaches often involve two successive steps. First, a panel of scFv or
Fab antibodies that specifically bind an antigen of interest are identified (for example, by screening a phage display
library). Second, the specifically-binding antibodies are tested for their ability to bind and/or inhibit the target antigen in
vivo. Because fewer than 1% ofscFvs are potentially useful as intrabodies (because they are not expressed and/or
cannot properly fold under the reducing conditions that exist within a cell), identification of a single scFv that can be used
as an intrabody requires the isolation of more than 100 scFv clones, a number that is unlikely to be obtained in most cases.
[0008] Application WO 00/54057 discloses a method for determining the ability of an immunoglobulin to bind to a
target antigen in an intracellular environment. The method disclosed consists of providing i) an intracellular immunoglob-
ulin associated with the a first molecule, and ii) an intracellular target antigen associated with a second molecule, then
in assessing the intracellular interaction between immunoglobulin to the target in intracellular, knowing that when the
first and second molecules are brought into stable interaction by binding of immunoglobulin to the target in intracellular
environment, a signal is generated. To evaluate the possibility to conduct this method in mammalian cells, a test has
been carried out with a first fusion protein comprising beta-galactosidase, and a second fusion protein the anti-beta-
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galactosidase scFvR4.
[0009] Application WO 01/48017 discloses a method for isolating an scFv with a framework which is stable and soluble
in a reducing environment. The method disclosed is performed by using a "two-hybrid assay" comprising the following
steps:
a) a scFv library with varied frameworks and constant CDRs is generated by mutation of at least one framework
encoding region of DNA sequence of a scFv to a known antigen and by introduction of such mutations into suitable
expression vectors,
b) host cells able to express a specific known antigen and only surviving in the presence of antigen-scFv-interaction
are transformed with said scFv library,
c) the thus transformed host cells are cultivated under conditions suitable to express the antigen and the scFv and
allowing cell survival only in the presence of antigen-scFv-interaction,
d) the scFv expressed in surviving cells and having a defined framework that is stable and soluble in reducing
environment is isolated.
[0010] Der Maur Adrian et al. (Methods, 34: 215-224, 2004) and Der Maur Adrian et al. (Journal of Biological Chemistry,
277(47): 45075-45085, 2002) disclosed methods for isolating an scFv with a framework which is stable and soluble in
a reducing environment.
[0011] Der Maur Adrian et al. (Methods, 34 : 215-224, 2004) teaches in Table 1 that of a total of 107 screened clones,
only 0.1% allow cell growth under selective conditions, and only 60% of these clones which allow cell growth under
selective conditions show scFv-dependent lacZ expression.
[0012] Laden et al. (Research in Microbiology, 153: 469-474, 2002) disclosed a mutant of a human anti-beta-galac-
tosidase single chain antibody fragment, called scFv13R4, and shown that scFv13R4 is able to fold properly in Escherichia
coli cytoplasm and is active in vivo in yeast since it is able to interact with beta-galactosidase in a two-hybrid assay.
[0013] Jung and plückthun (protein Engineering, 10(8): 959-966, 1997) discloses a method for improving in vivo folding
and stability of a single-chain Fv antibody fragment by using CDR grafting. The method is performed with the framework
of humanized 4D5 antibody.
[0014] Application WO 99/45959 discloses a humanized antibody framework motif wherein said framework has been
selected from a human library based upon comparison to a murine antibody, and the heavy chain is encoded by the VH
gene of K5B8, and the light chain is encoded by the VL gene of TR1.6.
[0015] However, none of the prior art documents recited above discloses an antibody library comprising at least 106
unique scFv antibody clone wherein each clones encodes a framework sequence identical to a framework encoded by
antibody clone scFv13R4 (SEQ ID NO: 32).
[0016] In view of the foregoing difficulties in producing and identifying antibodies that can be used as intrabodies for
use in medical and research applications, what is needed are more efficient methods of producing and selecting antibodies
that can be used as intrabodies.
SUMMARY
[0017] The inventors have described herein an antibody library that includes at least about 106 unique scFv clones,
wherein at least about 20% of the scFv clones encode an antibody that can detectably specifically bind a target antigen
within a cell when the antibody encoded by the scFv clone is expressed within the cell.
[0018] The inventors have also described herein an antibody library, wherein the antibody library includes at least
about 106 unique scFv antibody clones, wherein at least about 20% of the scFv antibody clones can be expressed within
an E. coli cell to produce soluble antibody at a level of at least about 5 mgs per liter of E. coli cells, wherein the E. coli
cells have been grown to an OD600nm of about 5.
[0019] In an aspect, of the invention described herein is an antibody library including at least about 106 unique scFv
antibody clones, wherein each unique scFv antibody clone encodes a unique scFv antibody comprising at least one of
a unique CDR3 VH sequence and a unique CDR3 VL sequence, and wherein the unique scFv antibody clones encode
a framework sequence substantially identical to a framework sequence encoded by scFv13R4 (SEQ ID NO: 32).
[0020] In the above antibody library of the invention, the unique scFv antibody clones can encode scFv antibodies
including a unique CDR3 VH sequence.
[0021] In the above antibody library of the invention, the unique scfv antibody clones can encode scFv antibodies
including a unique CDR3 VH, sequence.
[0022] In the above antibody library of the invention, the unique scFv antibody clones can encode scFv antibodies
including a unique CDR3 VL sequence.
[0023] In the above antibody library of the invention the unique scFv antibody clones can encode scFv antibodies
including a unique CDR3 VH sequence and a unique CDR3 VL sequence.
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[0024] The inventors have, described herein an scFv antibody that can be expressed as substantially soluble protein
under reducing conditions, wherein the scFv antibody is isolated from the library described above in the third aspect.
The scFv antibody can specifically bind to a target antigen under reducing conditions.
[0025] The inventors have described herein a method of producing an scFv antibody, including expressing the scFv
antibody described above in the fourth aspect within a cell, thereby producing the scFv antibody. The method can include
further purifying the scFv antibody from the cell.
[0026] In a second aspect of the invention, described herein is a method for preparing an scFv antibody library enriched
for scFv antibody clones that can be expressed within a cell, including: a) providing a first collection of scFv antibody
clones, wherein the first collection comprises clones comprising a unique sequence within a CDR3 loop of VH, wherein
the first collection has been enriched for scFv antibody clones that can be detectably expressed when introduced into
a cell; b) providing a second collection of scFv antibody clones, wherein the second collection comprises clones com-
prising a unique sequence within a CDR3 loop of VL, wherein the second collection has been enriched for scFv antibody
clones that can be detectably expressed when introduced into a cell; c) joining VH domains from scFv antibody clones
of the first collection with VL domains from scFv antibody clones of the second collection to obtain a third collection of
scFv antibody clones, wherein the third collection contains scFv antibody clones comprising a unique sequence within
the CDR3 loop of VH and a unique sequence within the CDR3 loop of VL, thereby preparing the scFv antibody library
enriched for scFv antibody clones that can be expressed within a cell.
[0027] In the above method for preparing an scFv antibody library, the first collection includes scFv antibody clones
that contain a VL sequence identical to an scfv13R4 (SEQ ID NO:33) VL sequence and the second collection can include
scFv antibody clones that contain a VH sequence identical to an scFv13R4 (SEQ ID NO:33) VH sequence.
[0028] In the above method for preparing an scFv antibody library, the first collection can include scFv antibody clones
that include identical CDR1 and CDR2 sequences in the VH domain and the second collection can include scFv antibody
clones that include identical CDR1 and CDR2 sequences in the VL domain.
[0029] In a third aspect of the invention, described herein is an antibody library produced by the method described
above in the sixth aspect.
[0030] The inventors also described herein an antibody selected from an antibody library produced by the method
described above in the second aspect.
[0031] In a ninth aspect, the invention features a method for constructing an antibody library including: a) selecting
an scFv antibody framework; b) introducing sequence diversity into a VH CDR3 region of the scFv antibody framework
to generate a first library including scFv antibody clones including a unique VH CDR3 region; c) introducing sequence
diversity into a VL CDR3 region of the scFv antibody frameworkto generate a second library including scFv antibody
clones including a unique VL CDR3 region; d) removing, from the first library, clones that do not detectably express scFv
antibody; e) removing, from the second library, clones that do not detectably express scFv antibody; and f) recombining
the first and second libraries to generate a final library comprising scFv antibody clones comprising a unique VH CDR3
region and a unique VL CDR3 region, thereby constructing the antibody library.
[0032] In the above method, the scFv is scFv13R4.
[0033] It is an object of the present invention to provide a novel antibody library for the isolation of scFvs expressed
in the cytoplasm that may be used as intrabodies.
[0034] It is another object of the present invention to provide a novel antibody library based on a single framework
and optimized for intracellular expression.
[0035] A further object of the present invention is to provide novel methods of constructing and validating a novel
antibody library for the isolation of scFvs expressed in the cytoplasm that may be used as intrabodies.
[0036] Another object of the present invention is to provide novel methods of constructing and validating a novel
antibody library based on a single framework and optimized for intracellular expression.
[0037] Still another object of the present invention is to provide novel methods of using an antibody library in order to
produce highly expressed scFvs that may be used as intrabodies.
[0038] Yet another object of the present invention is to provide novel methods of using an antibody library in order to
produce scFvs based on a single framework and optimized for intracellular expression.
[0039] These and other objects, features, and advantages of the present invention will become apparent after review
of the following detailed description of the disclosed embodiments.
BRIEF DESCRIPTION OF THE DRAWINGS
[0040]
Figure 1. (a) Schematic outline of the steps followed during library construction. The critical steps are: introduction
of tailored CDR3 loops in an unique human scFv framework; removal of non-expressed clones by fusion with the
CAT enzyme and selection on CAM plates; recombination of the 13 VH and 5 VL libraries, and display on phage.
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(b) Summary of the CDR3 loops collected in the database. (c) Distribution of the amino acids at each position of
the 5 amino acid long VH CDR3s from 55 rearranged human antibodies.
Figure 2. Schematic representation of CDR3 length distribution. Distribution of the CDR3 lengths in the database
and in 118 sequenced clones from the library .
Figure 3. Western blot analysis of twenty clones from the library that were cloned in a cytoplasmic expression vector
and expressed in E. coli under the control of the T7 promoter. Twenty clones from the library were cloned in a
cytoplasmic expression vector and expressed in E. coli under the control of the T7 promoter. Soluble extracts were
prepared, separated by SDS-PAGE, and analyzed by Coomassie staining (a) or Western-blot (b) using 9E10 and
an alkaline phosphatase conjugated anti-mouse IgG antibody (substrate BCIP/NBT). Each lane corresponded to 2
x 107 (2 X 10 to the 7th) cells. The arrow on the left indicates the position of the scFv.
Figure 4. Selected fluorescent micrographs of expression of randomly picked scFvs in HeLa cells. Cells were
transfected with scFv-EGFP constructs as indicated. 13R4 and 1F4 represent the positive and negative controls,
respectively. At 24 h post-transfection, cells were fixed and visualized under a fluorescent microscope with the
fluorescein isothiocyanate filter set. The micrographs represent typical fields containing a similar number of cells in
each case. Magnification: x 400.
Figure 5. Selection of binders against five purified proteins. (a) 2.5 3 1010 phages from each round of selection
were tested by ELISA against their respective antigen and revealed using an anti-M13 HRP conjugated monoclonal
antibody (Pharmacia). R0 is the non selected library and Rn the stock obtained after the nth round of selection.
Specificity was tested on BSA for the 3rd rounds of selection (A450 nm ~0.1 - 0.3). (b) Monoclonal phages from
each round of selection against GST:Syk protein were tested by ELISA as in (a). Percentage of soluble active scFvs
(Absorbance > 0.1) selected after three rounds against the indicated protein and expressed either in the periplasm
(gray) or in the cytoplasm (black).
Figure 6. Photomicrographs of the expression of anti-histones scFvs fused to EGFP in HeLa cells. The cells were
transfected and treated as indicated in the legend of figure 4. The pictures represent typical cells transfected with
scFv13R4 and three representative anti-histones clones (2, 5 and 10). D, DAPI staining (blue) merged with the GFP
signal.
Figure 7. Graphical representation of the expression of the activity of selected scFvs under reducing conditions.
Extracts of cells expressing the scFvs in the cytoplasm were prepared as in figure 3 in presence or absence of 10
mM DTT. ELISA was performed in presence or absence of DTT, accordingly. x-axis: amount of extract per well. y-
axis: ELISA signal at 450 nm.
Figure 8. Photomicrographs of double staining of HeLa cells using an intrabody and by immunofluorescence. HeLa
cells were transfected with anti-histones clone 5 (Figure 6) fused to the dsRed-monomer GFP. Microtubules were
revealed in the transfected cells by IF using the anti-tubulin scFv 2F12C (Table 3). Cells were observed at the
appropriate wavelength to visualize: (A) 2F12C scFv (microtubules alone); (B) clone 5 intrabody (histones alone);
(C) 2F12C and clone 5 (both microtubules and histones); (D) as C plus nucleus staining with DAPI.
DETAILED DESCRIPTION OF THE INVENTION
[0041] Provided herein are methods for constructing an scFv library enriched for scFvs that can be expressed within
a prokaryotic or eukaryotic cell. The scFvs maintain their structure under the reducing conditions present within a cell,
retain their ability to specifically bind a target antigen within a cell, and thus can be used as intrabodies in various
therapeutic and research approaches. Because the methods described herein can be used to produce libraries of scFvs
that are stable under reducing conditions, these libraries are also useful for producing scFvs that can be expressed by
and purified from prokaryotic or eukaryotic cells (e.g., by lysing the cells and purifying the desired scFv by well-known
techniques). Such purified scFvs are useful as antibodies for use in research, diagnostic tests, and for disease therapies.
[0042] An improved strategy for stabilizing scFvs to be used in vivo is to construct a scFv library tailored for intracellular
expression. Ideally, such a library should only contain scFvs able to fold under reducing conditions such as those found
in the cytoplasm of a cell. Another strategy is to construct an scFv library based on a single optimized antibody framework
for intrabody selection.
[0043] Described herein are methods for constructing a novel antibody library that is based on a single optimized
antibody framework and tailored for intracellular expression. Through molecular evolution, we obtained a human scFv
called scFv13R4, which is expressed at high levels in E. coli cytoplasm. In addition, this scFv is highly expressed, soluble,
and displays specific binding activity to a target antigen in yeast and mammalian cells. This scFv is very stable in vitro
and can be renatured in presence of a reducing agent. In addition, analysis of its folding kinetics showed that it folds
faster than the parent scFv and aggregates more slowly in vitro.
[0044] The human scFv library based on the framework of the optimized scFv13R4 contains more than a billion clones,
which is larger than previous libraries of 107 to 108. The diversity of the present human scFv library is much greater than
that of previous libraries because we designed the present library to encode VH and VL CDR3 loops of various different
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lengths. In addition, we used a biased mix of degenerate oligonucleotide sequences to encode CDR3 loops that mimic
human CDR3. Using optimized CDR3 loops and filtering steps to eliminate the non-expressed clones, we purged the
library of non-expressed scFvs and retained the cytoplasmically expressed scFvs without compromising the diversity of
the clones, as confirmed through testing with several proteins used as the antigens. Contrary to previously described
scFv libraries, most of the scFvs in the library are well expressed in E. coli and in mammalian cytoplasm.
[0045] This new approach to building scFv libraries allows facile and large-scale selection of functional intrabodies.
For example, several strong binders against different proteins, including the Syk and Auroroa-A protein kinases, the αβ
tubulin dimer, the papillomavirus E6 proteins, the core histones, gankyrin, and MAPK11-14, have been isolated from
the library. Some of the selected scFvs are expressed at an exceptionally high level in the bacterial cytoplasm, allowing
the purification of 1 mg or more of active scFv from only 20 ml of culture. Moreover, after three rounds of selection
against core histones as a target antigen, more than half of the selected scFvs were active when expressed in vivo in
human cells and were essentially localized in the nucleus. This new type of library, methods of creating and using such
libraries, and antibodies isolated from such libraries, are useful not only for the simple and large-scale selection of
functional intrabodies but also for the expression and purification of highly expressed scFvs that can be used in numerous
biotechnological, diagnostic, and therapeutic applications.
Intrabodies
[0046] Intrabodies are genetically-engineered antibody molecules that are ectopically expressed within cells. Intra-
bodies can be used to visualize or to inhibit a targeted antigen in living cells, and thus find use in various research and
medical (e.g., diagnostic and therapeutic) applications. However, intrabody technology has been limited by the fact that
fewer than 1% scFvs in a typical antibody expression library are stable enough to be expressed and/or active in vivo,
because the intracellular environment reduces the two conserved disulfide bridges that the vast majority of scFvs require
for stability. Described herein are methods of producing libraries of scFvs that are greatly enriched for scFvs that are
stable under reducing conditions and thus are suitable for use as intrabodies. The intrabodies can be used for various
research, diagnostic, and therapeutic approaches that employ intrabodies.
[0047] In most cases, obtaining efficient intrabodies currently requires two successive steps. First, a panel of antibodies
against the target antigen must be isolated. Due to the availability of very high quality naive antibody libraries displayed
on phage, this step is now easily accomplished by phage-display and can be automated in order to isolate binders
against several proteins in parallel. In a second step, these antibody fragments (scFv or Fab) must be tested in vivo for
their ability to inhibit their target. However, most scFvs do not fold properly under the reducing conditions found in the
cytosol and the nucleus of the cell where most of the interesting targets are located. This can result in aggregated and
inactive scFvs, which are unable to interact with their target. Since less than 1% of scFvs are efficient as intrabodies,
getting a single binder against a protein requires the isolation of 100 different scFvs, a number which is unlikely to be
obtained in most cases. This makes the process of identifying intrabodies from regular scFv libraries a difficult procedure
even when the screening is done in vivo using two-hybrid or equivalent systems. In addition, this low proportion of active
scFvs in the current libraries results in a 100-fold decrease in the potential repertoire screened, making the isolation of
intrabodies against different epitopes of the same protein unlikely.
Libraries
[0048] Described herein are novel phage-display libraries of scFvs optimized for intracellular expression and novel
methods of constructing and using the library. The library is constructed on a single antibody framework of a parental
scFv which was selected because of its improved activity inside the cytoplasm. The parental scFv is very stable, has
favorable folding and aggregation kinetics and is expressed at very high levels in all tested cell types. Having a single
framework for the construction of a library should allow more comparable expression levels between clones since most
of their sequences are conserved.
[0049] Because CDR sequences also play a role in scFv folding and expression, however, we believed that the
expression level of the clones would still exhibit some variability. To minimize these differences, we introduced variability
only within the CDR3 loops because these loops are the most variable in antibodies and are thus more likely to be highly
tolerant to sequence and length variations. Introduction of variability in the CDR3 is sufficient to generate antibodies
against most proteins. In addition, we carefully biased the frequencies of the amino acids in these loops so as to recover
the distribution observed among natural human sequences. When the expression levels of randomly selected clones
were compared in the cytoplasm, despite some clear differences, a high proportion of them were correctly expressed
both in E. coli and in mammalian cells. This proportion of intracellularly expressed scFvs is much higher than in previously
described libraries.
[0050] We were also able to select binders (i.e., antibodies that specifically bind to a selected target antigen) against
five different proteins (Aurora-A, GST:Syk, tubulin, histones, and E6 protein from papillomavirus HPV16). In subsequent
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studies we have also isolated binders against new targets including gankyrin and MAPK11-14. For MAPK11-14, the
four proteins involved are the four isoforms of the p38 MAP kinase. These proteins are very homologous (~60-74%
identity). In all cases we were able to isolate scFvs specific for the isoform used for the selection. This underlines the
specificity of the scFvs that can be isolated from this library.
[0051] A frequent concern when constructing scFv libraries is the simultaneous optimization of the library’s diversity
and size. Generally, the size of such a library is limited by the transformation efficiency to about 1010 clones. Given this
limited number of clones, it is thus of premium importance to avoid non-expressed scFvs or duplicates. To solve this
problem we first selected an antibody framework that was already optimized for intracellular expression, and then used
a two-step procedure to further optimize the library.
[0052] First, we constructed 18 "small" libraries for each CDR3 length (13 VH CDR3 lengths and 5 VL CDR3 lengths)
to be used for constructing the scFv library (see Example 1, herein below). Each of these 18 libraries was made by
replacing the corresponding CDR3 of the parental scFv13R4 by the randomized CDR3. The resulting library with one
and only one randomized CDR3 was then fused to the gene encoding chloramphenicol acetyltransferase (CAT), which
we used as a selectable marker. After transformation of each CDR3 library into E. coli, the libraries were plated on
chloramphenicol (CAM)-containing medium to select for those CDR3-CAT fusions that were expressed in the E. coli
cytoplasm. This step reduced the diversity of each library by about 10-30%.
[0053] Although the CAT gene is used in the examples provided herein, one of ordinary skill in the art will understand
that nucleic acids encoding any appropriate selectable marker can be fused with CDR3-encoding-nucleic acids and
used in the methods provided herein to enrich scFv libraries for scFvs that are expressed in prokaryotic or eukaryotic
cells. For example, suitable selectable markers for use in bacterial cells include, but are not limited to, the kanamycin
resistance gene. Examples of selectable markers for use in mammalian cells include but are not limited to, e.g., the
neomycin resistance gene, the puromycin resistance gene, and the hygromycin resistance gene. Examples of selectable
markers for yeast cells include URA3, HIS3, and purE. In addition, markers such as green fluorescent protein (GFP)
and derivatives thereof, beta-galactosidase, luciferase, or other luminescent, fluorometric, and/or colorimetric markers
can be used, in all types of cells, for example, with fluorescence-activated cell sorting (FACS), to enrich scFv libraries
for clones that encode scFvs that are capable of being expressed. One of ordinary skill in the art will understand how
to use the teachings herein, together with what is known in the art, to select an appropriate selectable marker and an
appropriate selection scheme to construct the scFv libraries described herein.
[0054] In a second step, we used PCR to randomly assemble the selected VH and VL libraries to generate the final
diversity, based on the hypothesis that if a newly-generated scFv clone containing a new CDR3 sequence in its VH
region plus the original VL of scFv13R4 was expressed, and if a newly-generated scFv clone containing a new CDR3
sequence in its VL region plus the original VH region of scFV 13R4 was expressed, then a recombined scFv clone
containing the new CDR3 sequence in its VH region plus the new CDR3 sequence in its VL region would also be
expressed, thereby resulting in a library containing only expressed scFvs. This was the case since 19 out of 20 clones
selected at random were expressed at least partially in a soluble form in E. coli cytoplasm. Importantly, since this selection
step was done early during the library construction, the diversity of the final library was only limited by the final transfor-
mation. This final recombination step, by generating a high diversity, ensured that all the clones were unique in the final
library. Altogether, this approach resulted in a library of 1.5 billion expressed and different scFvs.
[0055] Successful use of scFvs as intrabodies on a large scale requires several essential points to be fulfilled by the
library. First, the scFv must be easy to isolate. This is the case for the presently-described methods, since not only we
were able to isolate binders against all the tested proteins, but also a single cycle of selection was enough to get close
to 100% of binders. This very high enrichment rate is presumably due both to the high quality of the biased library which
contains only well expressed scFvs and to the use of the trypsin-sensitive helper phage KM13. This is of premium
importance since it may be possible to use a single panning cycle before in vivo testing of the scFvs as intrabodies,
allowing a better diversity of the targeted epitopes. Also, this high enrichment rate also reduces by a huge amount the
quantity of purified antigen needed for the panning steps. We were able to select on microtiter plates with as little as 1
mg of protein per well. Since further selection and confirmation of the binding activity by ELISA is not necessary because
of the very high proportion of binders, it is now possible to isolate good intrabodies with a very small amount of antigen.
Second, the scFv should be able to fold in all the cell compartments, particularly in the reducing ones such as the
cytoplasm and the nucleus. Again, this is the case for the scFv library described herein, since more than 80% of the
tested clones are at least partially soluble in the cell. In addition, we have shown that good cytoplasmic binders can be
obtained from the phage selected scFvs in E. coli and in eukaryotic cells.
[0056] Provided herein are antibody libraries that comprises at least about: 106, 5 X 106, 107, 5 X 107, 108, 5 X 108,
109, 1.5 X 109, 5 X 109, 1010, 5 X 1010, 1011, 5 X 10", 1012, 1013, 1014, 1015, or 1016 unique scFv clones, wherein at
least about: 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, or more of the scFv clones encode an antibody that can
detectably specifically bind a target antigen when the antibody encoded by the scFv clone is expressed within a cell
(e.g., as an intrabody). The scFvs described herein can be expressed to detectably specifically bind to a target antigen
in any prokaryotic or eukaryotic cell in which it would be desirable to detectably specifically bind a target antigen (e.g.,
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but not limited to, a bacterial cell, a yeast cell, an insect cell, an amphibian cell, an avian cell, a mammalian cell, and the like).
[0057] By "specifically binds" is meant that an scFv antibody preferentially binds to its target antigen rather than to
another antigen. By "detectably specifically binds" is meant that specific binding of scFv antibody to its target antigen
can be observed, e.g., but not limited to a phenotypic change in the cell in which the scFv antibody binds to its target
antigen, or detection of the interaction between the scFv antibody and its target antigen (e.g., co-localization of the scFv
antibody and its target antigen within a cell).
Exemplary Uses
[0058] Though the libraries described herein have been optimized for the isolation of intrabodies, the libraries can also
be used to select scFvs for diagnostic and therapeutic applications. Furthermore, because we designed the CDR3
diversity using expressed human sequences, the scFvs present in the library are fully human and should not induce an
anti-scFv antibody response in patients.
[0059] The libraries described herein and the antibodies produced by it are useful not only for identifying functional
intrabodies but also for the isolation of highly expressed scFvs that could be used in numerous biotechnological and
therapeutic applications. For example, the library and the antibodies produced by it may be have uses related to or
including, but not limited to, gene delivery strategies therapeutic agents, drug discovery tools, counteracting agglutination
of unwanted target molecules, combating disease states relating to misfolded protein disorders, and binding, neutralizing,
or modifying the function of a cancer-related target.
[0060] For example, the intrabodies described herein can be used to modulate the activity of syk tyrosine kinase and
other proteins implicated in allergic disorders (see, e.g., WO2005106481; see also Ulanova et al., Expert Opin Ther
Targets 2005, 9:901-921. MAP kinases (MAPK) are key mediators of cell proliferation and are often targeted for inhibition
in cancer therapy (see, e.g., Sebolt-Leopold JS and Herrera, R, Nat Rev Cancer, 4:937-947 (2004)) Other interesting
targets are microtubules and associated proteins (see Jordan MA and Wilson, L, Nat Rev Cancer, 4:253-265 (2004)).
[0061] Immunobodies can be used to treat or prevent diseases in commercially valuable plants, such as crops, e.g.,
using the methods described in Villani, ME et al. Immunomodulation of cucumber mosaic virus infection by antibodies
selected in vitro from a stable single-framework phage display library, Plant Molecular Biology 58(3):305 (2005)).
[0062] The intrabodies described herein can be used to treat, or prevent infections in human or animal cells. For
example, intrabodies can be used to treat, ameliorate, or prevent infection of cells by the human immunodeficiency virus,
using methods as described, for example, in Swan, CH et al, T-cell protection and enrichment through lentiviral CCR5
gene delivery, Gene Ther. 13:1480-1492.
[0063] The intrabodies described herein can be used to target proteins involved in neurological disorders, e.g., as
described, e.g., in Miller, TW et al (A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin’s
fragments in striatal models of Huntington’s disease, Neurobiol dis. 19:47-56 (2005)) and Miller and Messer (Intrabody
applications in neurological disorders: progress and future prospects, Mol. Ther. 12:394-401 (2005).
[0064] The intrabodies described herein can be used for cancer therapy by targeting a protein involved in cancer like
oncoproteins, as described, e.g., in Williams, BR and Zhu, Z (Intrabody-based approaches to cancer therapy: status
and prospects, Current med Chem 13:1473-1480 (2006) and Doorbar J. and Griffin H. (2007) Intrabody strategies for
the treatment of human papillomavirus-associated disease. Expert Opin. Biol. Ther. 7(5), 677-689.
[0065] The intrabodies described herein can be used to treat infections (e.g. but not limited to Epstein-Barr Virus) by
targeting a protein expressed by an infectious agent, e.g., as described in Fang CY et al (Modulation of Epstein0-Barr
Virus Latent Membrane Protein 1 Activity by Intrabodies, Intervirology 50:254-263 (2007)
[0066] As described herein, an intrabody can be administered to a cell by administering to the cell an expression vector
encoding the intrabody of interest. Expression vectors that are suitable for expression of intrabodies are well-known in
the art. Administration of expression vectors that encode the intrabodies described herein, can be achieved by any one
of numerous, well-known approaches, for example, but not limited to, direct transfer of the nucleic acids, in a plasmid
or viral expression vector, alone or in combination with carriers such as cationic liposomes. Such expression vectors
(which contain promoter and enhancer sequences suitable for expressing an operably-linked coding sequence when
the expression vector is introduced into a cell) and methods for making, using, and delivering such vectors to cells are
well known in the art and readily adaptable for use for administering intrabodies to cells.
[0067] Vectors can be any nucleotide construction used to deliver genes into cells, e.g., a plasmid or viral vector, such
as a retroviral vector which can package a recombinant retroviral genome (see e.g., Pastan et al., Proc. Natl. Acad. Sci.
U.S.A. 85:4486, 1988; Miller et al., Mol. Cell. Biol. 6:2895, 1986). The recombinant retrovirus can then be used to infect
and thereby deliver a nucleic acid of the invention to the infected cells. The exact method of introducing the altered
nucleic acid into mammalian cells is, of course, not limited to the use of retroviral vectors. Other techniques are widely
available for this procedure including the use of adenoviral vectors (Mitani et al., Hum. Gene Ther. 5:941-948, 1994),
adeno-associated viral (AAV) vectors (Goodman et al., Blood 84:1492-1500, 1994), lentiviral vectors (Naidini et al.,
Science 272:263-267, 1996), pseudotyped retroviral vectors (Agrawal et al., Exper. Hematol. 24:738-747, 1996). Physical
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transduction techniques can also be used, such as liposome delivery and receptor-mediated and other endocytosis
mechanisms (see, for example, Schwartzenberger et al., Blood 87:472-478, 1996). This invention can be used in con-
junction with any of these or other commonly used gene transfer methods. Appropriate means for transfection, including
viral vectors, chemical transfectants, or physico-mechanical methods such as electroporation and direct diffusion of
DNA, are described by, for example, Wolff, J. A., et al., Science, 247, 1465-1468, (1990); and Wolff, J. A. Nature, 352,
815-818, (1991).
[0068] Cell-permeable intrabodies (transbodies) can be administered to cells by fusing an scFv antibody with a protein
transduction domain (PTD) that allows the cell-permeable intrabody to cross the cell membrane and enter the cell, for
example, according to the methods described in Heng, BC and Cao, T (Making cell-permeable antibodies (Transbody)
through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies: potential
advantages over antibodies expressed within the intracellular environment (Intrabody), Med Hypotheses 64:1105-1108
(2005)). Alternatively, the scFv could be mixed with cationic lipids and delivered efficiently into cells, as shown with
complete antibodies (Courtête J., Sibler A.P., Zeder-Lutz G., Dalkara D., Zuber G. & Weiss E. (2007) Suppression of
cervical carcinoma cell growth by intracytoplasmic co-deiivery of anti-oncoprotein E6 antibody and siRNA. Mol. Cancer
Ther. 6, 1728-36). Such cell-permeable intrabodies can be used in cell culture (e.g., for research purposes) and for
diagnostic purposes (e.g., to detect a virus or microorganism in sample of cells from a human, animal, or plant suspected
of harboring an infectious agent. Such cell-permeable intrabodies can be administered to research animals (e.g. but not
limited to systemic administration, e.g., by intravenously administering an intrabody to a research animal, or by topical
administration, for example) to modulate the activity of a particular target antigen and thereby alter a phenotype in the
animal. Such cell-permeable intrabodies can also be administered to human or non-human animal patients to treat or
prevent disease or infection as described above. For example, cell-permeable intrabodies can be administered intrave-
nously, topically, orally, or by other well-known methods, as will be appreciated by one of ordinary skill in the art.
Use of the present scFv antibodies for large-scale antibody production
[0069] Because the scFv antibody clones encode antibodies that fold under reducing conditions, the libraries described
herein are also useful for identifying scFv antibodies that can be produced in large quantities by expressing the scFv
antibodies in cells (e.g., prokaryotic cells such as bacterial cells, or eukaryotic cells such as yeast cells, insect cells,
mammalian cells, or the like) and isolating the scFv antibodies from the cells. Single chain scFv antibodies for which it
would be desirable to purify large quantities of antibody include but are not limited to, for example, scFv antibodies that
are useful in laboratory research, for medical diagnostic tests, for commercial diagnostic tests or other types of diagnostic
tests (e.g., to detect contaminating microorganisms in drinking water or food), and for antibody therapeutics (e.g., to
treat cancer or to treat infectious or other types of diseases in which an antibody can be used to treat the disease).
[0070] Provided herein are antibody libraries for the isolation of expressed scFv antibodies, wherein the antibody
library comprises at least about: 106, 5 X 106, 107, 5 X 107, 108, 5 X 108, 109, 1.5 X 109, 5 X 109, 1010, 5 X 1010, 1011,
5 X 1011, 1012, 1013, 1014, 1015, or 1016 unique scFv antibody clones, wherein at least about: 20%, 25%, 30%, 35%,
40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, or more than 80% of the scFv antibody clones can be expressed within
a cell to produce soluble antibody at a level of at least about: 5 mgs, 8 mgs, 10 mgs, 15 ms, 20 mgs, 25 mgs, 30 mgs,
35 mgs, 40 mgs, 45 mgs, 50 mgs, or more than 50 mgs per liter of cells in a flask grown to an OD600nm of about 5.
[0071] There are many well-accepted approaches for expressing and purifying proteins such as expressed scFv
antibodies from cells and one of ordinary skill in the art will understand how to select the most appropriate type of cell
expression system from which to express and purify scFv antibodies. Many manuals that describe methods for protein
expression are known in the art. See, e.g., Current Protocols in Molecular Biology, John Wiley and Sons, 2006.
Definitions
[0072] By "unique sequence" is meant that, within a collection of scFv antibody clones, there are at least 106 clones
that contain a CDR3 sequence that is different from the CDR3 sequences of other clones within the collection of scFv
antibody clones. With reference to an scFv antibody clone or a library of such clones, a "unique sequence" is different
from the sequence present at the corresponding position within scFv13R4.
[0073] The terms "antibody framework" and "framework sequence" refer to any non-unique portion of the scFv antibody
clones, e.g., any portion of the scFv antibody that is not a unique CDR3 VH region and/or unique CDR3 VL region. As
referred to herein, the antibody framework or framework sequence is that of scFv13R4, the parental scFv clone upon
which the present libraries are based.
[0074] By "substantially identical" is meant that two or more amino acid sequences being compared are at least 98%,
98.5%, 99%, or 99.5% the same, or that two or more nucleic acid sequences being compared encode amino acid
sequences that are at least 98%, 98.5%, 99%, or 99.5% the same.
[0075] By "common sequence" is meant a nucleotide or amino acid sequence that is shared among scFv clones.
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[0076] By "scFv antibody clone" is meant a nucleic acid molecule that encodes an individual species of scFv antibody
that comprises a unique sequence within the VH CDR3 domain, the VL CDR3 domain, or within both VH and VL CDR3
domains.
[0077] By "target antigen" is meant an antigen that is preferentially bound by a particular antibody, compared to the
binding of that particular antibody to another antigen that is not a target antigen.
[0078] By "specifically binds" binds is meant that an antibody strongly and preferentially binds to a particular target
antigen, compared to the binding of the antibody to other antigens.
[0079] By "ectopically expressed" is meant that expression of an antibody of interest is not naturally expressed within
a particular type of cell in which the antibody is being expressed, i.e., the antibody is expressed within the cell because
an expression construct encoding the antibody has been introduced into the cell.
[0080] By "isolated" or "purified" is meant that an scFv antibody has been substantially separated, produced apart
from, or purified away from other biological components in the cell in which it has been produced, that is, substantially
separated away from other cellular components, such as other cellular proteins, DNA, RNA, lipids, and the like. The
term "isolated" or "purified" does not require absolute purity; rather, it is intended as a relative term. Preferably, an scFv
antibody is purified or isolated away from other cellular components such that the scFv antibody represents at least:
25%, 30%, 40%, 50%, 60%, 70% 80%, 90%, 95%, or greater, of the total content of the scFv antibody preparation.
[0081] By "soluble" antibody means that an antibody molecule is not in aggregate form. A soluble antibody has the
ability to specifically bind its target antigen.
[0082] By "substantially soluble" is mean that at least 20%, e.g., at least 25%, 30%, 40%, 50%, 60%, 70%, 80%, or
more of an scFv antibody as described herein is properly folded and thus can specifically bind its target antigen.
Example 1: Construction of an scFv library optimized for intracellular expression
MATERIALS
Bacterial strains, chemicals and enzymes
[0083] LB and 2xYT media were previously described (Miller, J.H. A Short Course in Bacterial Genetics: a Laboratory
Manual and Handbook for Escherichia coli and Related Bacteria. Cold Spring Harbor Laboratory Press; 1992). Strain
C-Max5F’ (Bio-rad laboratories) is E. coli K-12, [F’ lacIq Tn10] ϕ80dlacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1
hsdR17(rk- mk+) phoA supE44 λ- thi-1 gyrA96 relA1. MC1061 (ATCC #53338) is E. coli K-12, F-λ- hsdR2 hsdM+ hsdS+
mcrA mcrB1 araD139 Δ(ara-leu)7696 Δ(lacIPOZY)X74 galE15 galUgalK16 rpsL thi. Non-suppressor strain HB2151 is
E. coli K-12 [F’proA+B+ laclq lacZΔM15] ara Δ(lac-pro) thi. Chemicals were purchased from Sigma. Restriction enzymes
and cloned Taq polymerase were from Fermentas. ProofStart and Pfu DNA polymerases were respectively purchased
from Qiagen and Promega. Plasmid DNA, PCR and agarose-separated DNA were purified using Macherey-Nagel
Nucleospin kits.
Oligonucleotides
[0084] Eighteen spiked oligonucleotides used to introduce degenerate CDR3 loops were synthesized and purified
using high-pressure liquid chromatography (HPLC) by IBA GmbH (Goettingen, Germany). The sequences of the 18
spiked oligonucleotides is as follows.
[0085] H3_n = n amino acid long VH CDR3 loop; K3_n = n amino acid long VL kappa (κ) CDR3 loop; L3_n = n amino
acid long VL lambda (λ) CDR3 loop. For the degenerate positions, the percentages of the 4 bases are given as N(A/C/G/T).
The proportions of each nucleotide used at each spiked (degenerate) position is shown in Table I below.
H3_5:
[0086]
AGGGTGCCTCTGCCCCANNNNNNNNNNNNNNNTCTCACACAGTAATAAACAGCCG (SEQ ID NO: 1);
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[0087] Other oligonucleotides use to construct the libraries were synthesized by MWG and have the following se-
quences:
T7.back CCGGATATAGTTCCTCCTTT (SEQ ID NO: 19);
T7.for CTGCTAACCAGTAAGGCAAC (SEQ ID NO: 20);
M13rev-49 GAGCGGATAACAATTTCACACAGG (SEQ ID NO: 21);
M13uni-43 AGGGTTTTCCCAGTCACGACGTT (SEQ ID NO: 22);
scFvCAT.rev AACGGTGGTATATCCAGTGA (SEQ ID NO: 23);
scFvCAT2.rev CGGTGGTATATCCAGTGATTTTT (SEQ ID NO: 24);
PliaisonH3 TGGGGCAGAGGCACCCT (SEQ ID NO: 25);
PliaisonH3.back AGGGTGCCTCTGCCCCA (SEQ ID NO: 26);
PliaisonL3 GCAGTAATAATCAGCCTCGTCC (SEQ ID NO: 27).
Plasmids
[0088] Phagemid vector pCANTAB6 (McCafferty J et al., Appl Biochem Biotechnol 1994, 47:157-171) was used for
N-terminal fusion of NcoI/NotI-scFv fragments to the minor coat protein pIII of filamentous phage M13. This phagemid
is derived from pUC 119 and contains the following sequences in the following order: a lac promoter, the pelB leader
sequence, NcoI and NotI sites for scFv cloning, a His6 and a c-myc tag recognized by the 9E10 monoclonal antibody,
an amber codon and the pIII gene sequence.
[0089] For cytoplasmic expression of the scFvs in E. coli we used plasmid pET23NN. This plasmid is derived from
pET23d(+) (Novagen) and contains a T7 promoter, followed by a NcoI site containing the ATG initiator, a NotI site
followed by a c-myc and a His6 tag.
[0090] Plasmid pscFv CAT is derived from pTrc99A and contains a tac promoter, followed by a NcoI site containing
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the ATG initiator of an out-of-frame scFv, a NotI site followed by the CAT gene. When a scFv is inserted within the NcoI-
NotI sites, the scFv is expressed as a fusion with the CAT protein. The construction was done as follows: first, the unique
BstEII site of pTrc99A (A13038) was removed by digestion followed by 5’ overhang fill-in to form blunt ends, and ligation.
The resulting plasmid was digested with NcoI and NotI, and the 4210bp fragment purified (fragment I). Second, the
unique NcoI site of plasmid pACYCI 84 (X06403) located within the CAT gene was removed by site directed mutagenesis
by changing the Thr 172 codon from ACC to ACG. Then the CAT gene was amplified by PCR using CAT-NotI.for
(TAAGGCGGCCGCAATGGAGAAAAAAATCACTG; SEQ ID NO: 28) and CAT-HindIII.back (ACTGCCTTAAAAAGCT-
TACGCC; SEQ ID NO: 29). In the oligonucleotide sequences, the introduced restriction sites are underlined and the
beginning and the end of the CAT gene are in bold-italic. The 660 bp PCR fragment was digested by NotI and HindIII,
and purified (fragment II). Third, a 750 bp NcoI-NotI scFv13E6 fragment (a grafted version of the scFv13R4 containing
the CDR loops of an anti-E6 monoclonal antibody. Philibert et al., to be published) was purified (fragment III). Fourth,
the three fragments I, II and III were ligated to give plasmid pscFvCAT. Finally, an internal deletion of 165 bp was
introduced in the scFv by removing the fragment. between the two PstI sites of the gene. The resulting plasmid, called
pscFvCAT, is AmpR and CAMs since the deletion of the PstI fragment resulted in a frameshift in the scFv.
[0091] Plasmid p513-EGFP is a derivative of pSG5 (Green, S., et al. Nucleic Acids Res 1988, 16:369) and harbors
the EGFP coding region (Clontech, Inc.) under the control of the SV40 early promoter. The p513-scFv-EGFP constructs
correspond to in frame fusions of the scFv’s and the EGFP coding region with a linker of 10 residues.
[0092] The scFv coding regions were amplified with oligonucleotide primers
5’-ACTGATAAGCTTGCCACCATGGCCGAGGTGC (SEQ ID NO: 30)
and 5’-TTGATTACTAGTGAGTTTTTGTTCTGCGGCC (SEQ ID NO: 31)
and inserted into the HindIII-SpeI digested p51 3-EGFP vector.
Optimized Antibody Framework
[0093] To maximize the effectiveness of the scFv library, construction of the library begain with the selection of a single
optimized antibody framework for intrabody selection. Through molecular evolution, a human scFv called scFv13R4
was obtained, which is expressed at high levels in E. coli cytoplasm. This scFv is also expressed and has a soluble and
active conformation in both yeast and mammalian cells. This scFv is very stable in vitro and can be renatured in presence
of a reducing agent. In addition, analysis of its folding kinetics showed that it folds faster than the parent scFv and
aggregates more slowly in vitro. The mutations isolated are mainly located in the VH domain and seem to be highly
specific to this particular scFv since they cannot be transferred to a very homologous VH domain. The nucleotide and
amino acid sequences of scFv13R4 are shown below.
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METHODS
Database of CDR3 sequences
[0094] Release 5 (August, 1992) of the Kabat database was used (Johnson, G., and Wu, T.T.: Kabat Database and
its applications: 30 years after the first variability plot. Nucleic Acids Res 2000, 28:214-218). This dataset contained
44990 sequences. First, 4643 human VH sequences which were not a pseudogene and were not humanized were
extracted. H3 sequences were then extracted from this dataset, first taking into account the nucleotide sequence when
present, then the amino acid sequence. Finally, the 3469 complete H3 sequences that contained only the 20 regular
amino acids were kept, among which 2703 were unique. The same procedure was followed for λ and κ light chains,
respectively, resulting in 1044 and 1291 sequences from which 775 and 828 were unique.
[0095] CDR3 sequences from the IMGT/LIGM-DB database as it existed on 27 November 2003 were also extracted
(Giudicelli, V., et al. IMGT/LIGM-DB, the IMGT(R) comprehensive database of immunoglobulin and T cell receptor
EP 2 134 841 B9
21
5
10
15
20
25
30
35
40
45
50
55
nucleotide sequences. Nucleic Acids Res 2006, 34:D781-784). Only the "productive/regular/human/cDNA+RNA/rear-
ranged" genes were considered. 5179 H3, 1432 K3, and 1131 L3 sequences were obtained, of which 4323 H3, 974 K3,
and 812 L3 sequences were unique.
[0096] 127 additional human antibody sequences were also collected from the Protein data bank (Berman, H.M., et
al. The Protein Data Bank. Nucleic Acids Res 2000, 28:235-242.). For this we used the file of 510 sequences already
compiled by Andrew Martin on August 19, 2003 (Allcorn, L.C., and Martin, A.C.R. SACS-self-maintaining database of
antibody crystal structure information. Bioinformatics 2002, 18:175-181).
Spiked oligonucleotide design
[0097] In biasing the representations of the amino acids, optimized mixtures of the nucleotides at each of the three
codon positions were calculated as described previously (Wang, W., and Saven, J.G. Designing gene libraries from
protein profiles for combinatorial protein experiments. Nucleic Acids Res 2002, 30:e120; Park, S., et al. Progress in the
development and application of computational methods for probabilistic protein design. Comput Chem Eng 2005,
29:407-421.). Premature termination of protein sequences was limited by imposing an upper bound of 0.05 on the
probability of realizing a stop codon. For the 34 positions which did not satisfactorily recover the desired probabilities of
the amino acids, a second optimization was done with the same method, but with no constraint on the stop codon
frequency. For oligonucleotide synthesis, the calculated frequencies were rounded in increments of 5% as follows: all
the frequencies between 0% and 5% were rounded to 5%; other frequencies were rounded to the nearest 5%; if the
resulting sum was higher than 100%, 5% was removed from the rounded amino acid frequency larger than 5% for which
the difference between the rounded and the target frequency was maximal and the process iterated until the sum was
100%; if the sum was lower than 100%, 5% was added to the rounded frequency lower than 95%, for which the difference
between the rounded and the target frequency was maximal and the process iterated until the sum was 100%.
Construction of VH and VL libraries
[0098] Variable CDR3 sequences were introduced in scFv13R4 by PCR assembly using a hot-start proofreading
polymerase (ProofStart, Qiagen) using as a template plasmid pAB 1-scFv13R4p (Martineau, P., and Betton, J.M. In
vitro folding and thermodynamic stability of an antibody fragment selected in vivo for high expression levels in Escherichia
coli cytoplasm. J Mol Biol 1999, 292:921-929.) To introduce random H3 loops, the 5’ of the gene with the random H3
sequence was obtained with oligonucleotides M13rev-49 and one of the 13 degenerate oligonucleotides, and the 3’ was
obtained with PliaisonH3 and M13uni-43 (both for 20 cycles at 55°C). The two purified bands were thus assembled by
PCR (30 cycles, 55°C) using M13rev-49 and M 13uni-43. The resulting PCR was purified using a commercial kit (Nu-
cleospin, Macherey-Nagel), digested for 16 hours at 37°C with NcoI and NotI enzymes, and then purified on a gel. The
same procedure was followed to introduce random L3 and K3 loops except that the pairs of primers used were M13rev-
49/PliaisonL3 for the 5’ and one of the degenerate oligonucleotides encoding the L3/K3 loop (K3_n or L3_n) with M13uni-
43 for the 3’ part of the gene.
[0099] Each digested band was ligated for 16 hours at 16°C with 1 mg of NcoI-NotI, digested, and purified pscFvΔCAT
in 100 ml using 10 Weiss units of T4 DNA ligase. The ligation was heat inactivated and purified using a commercial kit
(Nucleospin). The ligation was then electroporated in 300 ml of MC 1061 competent cells (Sidhu, S.S., et al. Phage
display for selection of novel binding peptides. Methods Enzymol 2000, 328:333-363) and plated on a 600 cm2 square
plate of LB containing 100 mg/ml of ampicillin, then incubated for 16 hours at 37°C. The 18 libraries (13 VH and 5 VL)
were scrapped in 10 ml of LB with 10% glycerol, and 109 bacteria were immediately plated on a 600 cm2 square plate
of LB containing 100 mg/ml of ampicillin, 1 mM IPTG and 30 mg/ml of CAM, then incubated for 16 hours at 37°C. The
18 libraries were then scrapped in 10 ml of LB with 10% glycerol and frozen at -80°C. An aliquot was used to prepare
DNA for the library assembly.
Library assembly
[0100] The 13 VH libraries were amplified using primers M13rev-49/PliaisonH3.back using Pfu polymerase, and the
5 VL libraries were amplified using scFvCAT.rev/H3_Liaison (30 cycles, 55°C). The 18 PCR bands were first purified,
then carefully quantified on gel using ImageJ software. The 13 VH bands were pooled in amounts proportional to their
frequency in human H3. This mix was called VHpool. The 2 VL κ bands were pooled in order to obtain 75% of 9 amino
acid-length loops and 25% of 10 amino acid-length loops. The VL λ bands were pooled to obtain 30% of the 9, 30% of
the 10, and 40% of the 11 amino acid-length loops. Finally, the κ and λ mixes were pooled in order to get 50% of each
class in the final mix called VLpool.
[0101] VHpool and VLpool were assembled by PCR using Taq DNA polymerase and primers M13rev-49/scFvCAT2.rev
in 500 ml (30 cycles, 55°C). The PCR was successively digested with 20 units of NcoI and NotI for at least 6 h each,
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purified, and then quantified on gel. 50 mg of vector pCANTAB6 was successively digested with 80 units of NcoI and
NotI for at least 6 h each, purified then quantified on gel. 5 mg of linearized pCANTAB6 was ligated with an equal molar
amount of insert (0.84 mg) in 500 ml at 16°C using 50 Weiss units of T4 DNA ligase. The ligation was heat inactivated
and purified using a commercial kit (Nucleospin). The purified ligation was then electroporated in 10 3 300 ml of C-
Max5αF’ competent cells (Sidhu, S.S., et al. Phage display for selection of novel binding peptides. Methods Enzymol
2000, 328:333-363), and plated on ten 600 cm2 square plate of LB containing 1% of glucose and 100 mg/ml of ampicillin.
After incubation for 16 h at 37°C, cells were scrapped in 2xYT containing 10% of glycerol and kept frozen at -80°C in
aliquots corresponding to twenty times the diversity.
Antigens
[0102] Aurora-A is an His-tagged protein and was produced in E.coli. GST:Syk was expressed in E.coli. (Dauvillier,
S., et al. Intracellular single-chain variable fragments directed to the Src homology 2 domains of Syk partially inhibit Fc
epsilon RI signaling in the RBL-2H3 cell line. J Immunol 2002, 169:2274-2283). E6 protein from papillomavirus HPV16
was expressed in cyanobacterium Anabaena (Desplancq et al., to be published). Histones (a mix of H2a, H2b, H3 and
H4) were purchased from Sigma (type II-AS. #H7755). Tubulin was purified from pig brain (Williams, R.C.J., and Lee,
J.C. Preparation of tubulin from brain. Methods Enzymol 1982, 85 (Pt B):376-385).
Library rescue and selection
[0103] Library rescue was done essentially as previously described using a trypsin-sensitive helper phage (Kristensen,
P., and Winter, G. Proteolytic selection for protein folding using filamentous bacteriophages. Fold Des 1998, 3:321-328).
Briefly, an aliquot of the library corresponding to a 10 to 20-fold excess over the diversity (2-3 x 1010 bacteria) was
inoculated in 1000 ml of 2xYT containing 100 mg/ml ampicillin and 1% glucose and grown with shaking at 37°C until
OD600nm was 0.7. 200 ml (∼3 3 1010 cells) were infected with 5 3 1011 helper phage KM 13 (Kristensen, P., and Winter,
G. Proteolytic selection for protein folding using filamentous bacteriophages. Fold Des 1998, 3:321-328) and incubated
without shaking for 30 min at 37°C. Cells were pelleted, resuspended in 1000 ml of 2xYT containing 100 mg/ml ampicillin
and 25 mg/ml kanamycin and incubated overnight with vigorous shaking at 30°C. The supernatant containing phages
was precipitated twice by adding 1/5th of the volume of PEG-8000 20%, NaCl 2.5 M, and resuspended in PBS supple-
mented with 15% of glycerol. Aliquots containing 1011-1012 phages were stored at -80°C.
[0104] To select for binders, 100 ml of purified antigens were coated in a Nunc Maxisorp 96-well plate. For the first
round, an antigen concentration of 10-100 mg/ml was used. For subsequent rounds, an antigen concentration of 1-10
mg/ml was used. The plate was washed 3 times with PBS containing 0.1% of Tween20 (PBST) and saturated for 2 hours
at room temperature with PBS containing 2% non-fat milk (MBPS). 1011-1012 phages were added per well in 2% MPBS
and incubated for 2 hours at room temperature. The plate was washed 20 times (first round) or 40 times (2nd and 3rd
rounds) with PBST, and then washed 3 times with PBS. Excess PBS was removed, and the phages were eluted by
adding 100 ml of 100 mM triethylamine for 10 minutes at room temperature. The eluted phage suspension was neutralized
with 50 ml of 1 M Tris-HCl pH 7.4, then digested 15 minutes at room temperature with trypsin by adding 1.5 ml of 0.1 M
CaCl2 and 15 ml of 10 mg/ml TPCK-treated trypsin (Sigma). 1 ml of a 37°C exponentially growing Cmax5aF’ strain in
2xYT was infected with 40 ml of trypsin-treated phages, incubated 30 min at 37°C without shaking, then plated on a 15
cm round Petri dish (LB, 100 mg/ml ampicillin, 1% glucose). After overnight incubation at 37°C, bacteria were recovered
from the plate and used to prepare a new stock of phages using KM13 helper phage. 1011-1012 phages of this stock
were used for the next round of selection.
Periplasmic and cytoplasmic screening
[0105] For periplasmic screening, phages from round 3 were used to infect the non-suppressive strain HB2151. Indi-
vidual clones were tested for scFv expression by ELISA on antigen-coated 96-well microtiter plates as described (Har-
rison, J.L., et al. Screening of phage antibody libraries. Methods Enzymol 1996, 267:83-109.) For cytoplasmic screening,
plasmid was prepared from the pool of bacteria of the 2nd or 3rd selection round, digested with NcoI and NotI enzymes,
and the 750 bp band was cloned in NcoI-NotI digested and dephosphorylated plasmid pET23NN. Ligation was trans-
formed in C-Max5αF’, and the cells were plated on LB with 100 mg/ml ampicillin and incubated for 16 hours at 37°C.
Cells were scrapped, and the plasmid DNA was prepared and used to transform chemically competent BL21(DE3)
pLysS. Individual clones were grown in a 96-well microtiter plate containing 100 ml of 2xYT, 100 mg/ml of ampicillin with
vigorous shaking at 37°C until OD600nm reached 0.6. IPTG was added to 0.4 mM final and the microtiter plate was
incubated for 16 hours at 24-30°C with vigorous shaking in a humidified atmosphere. After centrifugation, cells were
resuspended in 100 ml of 50 mM Tris-HCl pH7.5, 5 mM EDTA, freeze/thawed, and incubated 1 hour on ice. MgCl2 was
added up to 10 mM and the DNA was digested with 10 mg/ml of DNAseI. 5-20 ml were used in an ELISA on an antigen-
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coated 96-well microtiter plate (Nunc Maxisorp). Revelation was done using 9E10 monoclonal antibody followed by an
HRP conjugated anti-mouse IgG antibody.
Purification of scFv
[0106] scFvs cloned in plasmid pET23NN were purified from the cytoplasm of BL21(DE3) pLysS and purified on a Ni-
NTA column as described for the parental scFv13R4 (Martineau, P., et al. Expression of an antibody fragment at high
levels in the bacterial cytoplasm. J Mol Biol 1998,280:117-127.).
Cell transfection and immunofluorescence
[0107] HeLa cells were maintained in Dulbecco’s modified Eagle’s tissue culture medium (DMEM; Invitrogen) supple-
mented with L-glutamine (2 mM), penicillin (100 IU/ml), streptomycin (25 mg/ml) and 10% heat-inactivated fetal calf
serum at 37°C in a humidified 5% CO2 atmosphere. Transient transfection was carried out with the TransFectin lipid
reagent (Bio-Rad, Hercules, CA, USA) according to the manufacturer’s instructions. Cells were seeded on coverslips
in 6-well plates at 2.5 3105 cells/well the day before transfection. 1 mg DNA and 2 ml of reagent diluted in 100 ml of
DMEM were mixed and left at room temperature for 20 minutes. Cells were grown at 37°C for 24 hours after addition of
the mixture. The expressed GFP-tagged proteins were visualized after fixation of the transfected cells with 4% parafor-
maldehyde in PBS for 45 minutes at room temperature. After extensive washing with PBS, cells were dried and mounted
with Fluoromount-G (SouthernBiotech, Birmingham, UK). The processed cells were examined with a Zeiss Axioplan
fluorescence microscope equipped with an Olympus DP50 camera. Images were collected with a Zeiss 403 plan-
neofluar objective and processed using Adobe Photoshop 5.5. For Figure 8, HeLa were transfected with anti-histones
clone 5 fused to the dsRed-monomer GFP, fixed as above and permeabilized with Triton 3-100 (0.2%, 5 min). The
microtubule network was revealed with the 2F12C scFv (Table 3) at 3 mg/ml using the 9E10 anti-myc and an Alexa Fluor
488 anti-mouse IgG antibody. Cells were observed by confocal microscopy (363).
RESULTS
Step 1: Selection of Antibody Framework
[0108] In order to maximize the effectiveness of the scFv library, construction of the library begain with the selection
of a single optimized antibody framework for intrabody selection. Through molecular evolution, a human scFv called
scFv13R4 was obtained, which is expressed at high levels in E. coli cytoplasm. This scFv is also expressed and has a
soluble and active conformation in both yeast and mammalian cells. This scFv is very stable in vitro and can be renatured
in presence of a reducing agent. In addition, analysis of its folding kinetics showed that it folds faster than the parent
scFv and aggregates more slowly in vitro. The mutations isolated are mainly located in the VH domain and seem to be
highly specific to this particular scFv since they cannot be transferred to a very homologous VH domain. The nucleotide
and amino acid sequences of scFv13R4 are shown below.
Step 2: Introduction of Diversity into CDR3 Sequences
a)Database of human CDR3 sequences
[0109] Human CDR3 sequences were compiled from three main sources: the Kabat database (Johnson, G. and Wu,
T.T. Kabat Database and its applications: 30 years after the first variability plot. Nucleic Acids Res 2000, 28:214-218),
the IMGT database (Giudicelli, V., et al. IMGT/LIGM-DB, the IMGT(R) comprehensive database of immunoglobulin and
T cell receptor nucleotide sequences. Nucleic Acids Res 2006, 34:D781-784), and the RCSB PDB (Berman, H.M., et
al. The Protein Data Bank. Nucleic Acids Res 2000, 28:235-242). After removing the duplicates, the database contained
5179 H3, 1432 K3, and 1131 L3 CDR3 unique sequences. It can be noted that most of the H3 sequences were unique
since, for instance, in the Kabat database, 2368 H3 sequences (88%) were found only once among the 2703 complete
H3 sequences. The result was comparable in the case of L3 and K3 since, respectively, 87% and 82% of the sequences
were unique in the Kabat database. This underlines the very high variability of the human CDR3 sequences.
[0110] This variability, however, is not evenly distributed in the loop, and the frequency of each amino acid varies from
one position to another and for each loop length. In addition, the amino acid distribution depends on the origin of the
antibody sequence. This bias can be due to a structural constraint as for instance in the case of the antepenultimate
residue which is frequently an aspartate (D101 using Kabat numbering scheme) and plays an important role in the switch
between the extended and the kinked conformation of the H3. In other cases, this bias may only be due to the limited
number of sequences available for the D and J segments, and amino acids other than those found in natural antibodies
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may be tolerated.
[0111] For the construction of the library it was decided to make CDR3s that mimic the natural distribution for two main
reasons: i) one goal was to general scFvs that would be as human as possible for possible use in human therapy; and
ii) maintaining the natural amino acid distribution will be more likely result in functional antibodies.
[0112] CDR3 sequences from the database were aligned by length, and the frequency for each of the 20 possible
amino acids at each position and for each loop length were calculated. In the case of the light chain CDR3s, sequences
were analyzed independently for each class. In the case of the H3 sequences, this resulted in 35 tables, one for each
H3 length between 1 and 34 amino acids. For a loop of length n, this table contained 20n frequencies.
b) Oligonucleotide design for encoding CDR3 loops
[0113] Eighteen oligonucleotides were designed to follow the amino acid distribution found in the compiled CDR3
database. One-hundred-ninety-two optimized mixes of the four nucleotides at each position of the codon were used, to
match as well as possible with the desired amino acid distribution. The main advantage of this approach is that it only
requires classical oligonucleotide synthesis resulting in better oligonucleotide quality. Due to the restrictions of the genetic
code, however, it is not possible to follow precisely an arbitrary amino acid distribution. In addition, if the library does
not strictly follow the natural amino acid distribution, this may introduce interesting non-natural diversity in the CDR3 loops.
[0114] Optimized mixes for the 249 variable positions were first calculated to match the distribution with a minimal
frequency of stop codons, then 34 positions which were too distant from the target distribution were further optimized
by relaxing this last constraint. Due to the constraint of the genetic code, some positions were not perfectly optimized.
For instance, at position 3, alanine and glycine were under-represented in our mix and it was necessary to introduce a
substantial amount of some non-naturally found amino acids like cysteine in order to match other amino acid frequencies.
There was, however, a good overall agreement between the database and the oligonucleotide-encoded frequencies
since the most frequently found amino acids were represented at the highest rates in the library and the rare amino
acids were usually present at a low frequency. The sequences of the 18 degenerate oligonucleotides used to construct
the CDR3 loops are provided above.
c) Construction of CDR3 loop libraries for VH and VL chains
[0115] Independent libraries for each CDR3 loop length were constructed. This was done independently for each of
the heavy and the two classes of light chains. For each library, random CDR3 loops were introduced by PCR and the
resulting library was then cloned back in the scFv 13R4 gene, which was fused to the CAT gene in vector pscFvCAT.
This resulted in libraries of scFv13R4 clones with one and only one randomized CDR3 loop.
[0116] The 5 amino acid long H3 loop library was constructed first. Forty-three randomly chosen clones were se-
quenced. Some positions diverged from the expected values of frequencies for the 20 amino acids, but on average, the
distribution of amino acids in the library matched the expected distribution. This showed that the quality of the oligonu-
cleotides was good and that the resulting library followed the natural distribution of the amino acid in human H3 loops.
Table 2
Diversity of the CDR3 libraries
CAM phenotypeb
Initial diversitya ++ + - final diversityc
H3-5 1.4e8 15/20 3/20 2/20 1.1e8
H3-6 2.7e7 20/20 0/20 0/20 2.7e7
H3-7 9.2e7 16/20 3/20 1/20 7.4e7
H3-8 5.0e6 14/20 4/20 2/20 3.5e6
H3-9 2.4e8 16/20 1/20 3/20 1.9e8
H3-10 1.0e7 10/20 6/20 4/20 5.0e6
H3-11 2.2e7 9/12 1/12 2/12 1.7e7
H3-12 1.0e7 15/20 2/20 3/20 7.5e6
H3-13 2.3e7 8/12 3/12 1/12 1.5e7
H3-14 1.0e7 12/20 4/20 4/20 6.0e6
H3-15 2.1e7 8/12 3/12 1/12 1.4e7
H3-16 1.0e7 12/20 2/20 6/20 6.0e6
H3-17 1.1e7 12/20 4/20 4/20 6.6e6
K3-9 3.6e6 11/16 1/16 4/16 2.5e6
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Step 3: Removal of Non-Expressed Sequences
[0117] As expected, not all of the clones formed from the construction of the VH and VL libraries were functional for
three main reasons: i) oligonucleotides used to introduce diversity may contain stop codons; ii) stop codons or frameshifts
may be introduced by the PCR and the cloning steps; or iii) the scFvs are poorly expressed in the cytoplasm. To remove
these non-functional scFv clones, expressed clones were selected by fusing the scFv gene and the chloramphenicol
acethyl transferase (CAT) enzyme using the method of Maxwell KL et al. (A simple in vivo assay for increased protein
solubility, Protein Sci 1999; 8:1908-1911) as described below.
Creation of scFV-CAT fusion proteins
[0118] Briefly, the scFv libraries were independently cloned between the NcoI and NotI sites of vector pscFvCAT under
the control of the tac promoter and in frame with a downstream CAT gene. The scFv-CAT fusion protein was thus
expressed in the cytoplasm. If a scFv was not properly expressed because of the inclusion of a stop codon or frameshift
mutation, or if it was unable to fold in the cytoplasm, the resulting scFv-CATprotein would be either not expressed or
not active, resulting in a chloramphenicol sensitive (CAMs) phenotype. On the other hand, if the scFv was properly
expressed, the resulting scFv-CAT protein would be well expressed in the cytoplasm, and the bacterium would be
chloramphenicol resistant (CAMR). By adjusting the chloramphenicol (CAM) concentration, one can even select for
expression of different solubility levels of the scFv-CAT protein.
[0119] Different CAM concentrations were tested for this selection step ranging from 15 to 200 mg/ml. At the highest
concentration of CAM, the library was enriched in well-expressed scFvs, but also in clones containing recombined
plasmids harboring partial or complete deletions of the scFv gene. Next, the libraries were plated on a medium CAM
concentration (30 mg/ml). This concentration was high enough to remove all the non-expressed or strongly aggregating
scFvs, but did not result in a detectable amount of plasmids harboring scFv deletion.
[0120] To estimate the final size of the libraries, at least 12 clones were isolated from each initial library, which was
selected on ampicillin and on CAM to determine the fraction of CAMR clones. Some clones grew quickly and formed
colonies on ampicillin/CAM/IPTG plates (Table 2, column ++), some grew slowly (column +), and some did not grow at
all (column -). The size of the libraries of expressed scFv (selected on Amp+CAM+IPTG) was thus estimated as the
product of the original library size (selected on ampicillin) by the frequency of the CAMR clones. The sizes of the 18
libraries are given in the last column of Table 2 and ranged from 2.5x106 to 1.9x108.
Step 4: Assembly of CAM-selected library
[0121] The final library was assembled by recombining the 13 CAM-selected VH libraries with the 5 CAM-selected VL
libraries. The theoretical possible diversity is about 1015 (∼13 VH x 107 x 5 VL x 106). This is much larger than a library
(continued)
Diversity of the CDR3 libraries
CAM phenotypeb
Initial diversitya ++ + - final diversityc
K3-10 4.4e6 10/16 1/16 5/16 2.8e6
L3-9 1.7e7 11/20 6/20 3/20 9.4e6
L3-10 1.5e7 10/20 9/20 1/20 7.5e6
L3-11 1.8e7 15/20 3/20 2/20 1.4e7
a Initial diversity of the library cloned as fusion with CAT and selected
on ampicillin. This is the number of clones obtained after transforma-
tion.
b Between 12 and 20 clones from the transformation were checked
on CAM plates. Plates were incubated for 16 h at 37°C and colony
size estimated. Columns ++,+ and - give, respectively, the fraction of
clones that grew normally, gave tiny colonies, and did not grow at all.
c Diversity of the libraries selected on CAM. The diversity is estimated
from column "Initial Diversity" and "CAM phenotype" by assuming
that the final diversity is close to (Initial Diversity) 3 (CAM phenotype
++). The real diversity may be a higher since some of the clones noted
+ in column "CAM phenotype" may be present in low abundance.
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that could be obtained by electroporation. It is thus very unlikely to obtain twice the same clone in the final library.
[0122] The 13 VH and 5 VL libraries were amplified by PCR with an overlapping sequence of 17 nucleotides, then
purified and quantified on agarose gel. The VH and VL purified fragments were then pooled in amounts proportional to
the natural distribution of the CDR3 loop lengths in human antibodies (Figure 3a). Finally, the VH and VL mixes were
assembled by PCR, digested and cloned in a vector suitable for phage display. The library was electroporated in strain
Cmax5αF’, resulting in a library of 1.5x109 clones containing a scFv insert, as checked by PCR on 100 randomly picked
colonies. The 18 CAM-selected libraries were assembled in amounts proportional to the natural distribution of CDR3
loops lengths in human antibodies to form a final library of more than a billion clones.
[0123] One hundred and eighteen clones were sequenced to determine loop lengths and sequences. Almost all loop
lengths were found in the library. 11 and 16 amino acid long loops were also under-represented in the library. This is
presumably due to the poor quality of these oligonucleotides as shown by their profile on an Agilent Bioanalizer. Loop
lengths ranging from 7 to 12 were over-represented in the library but only by a two-fold factor. The loop lengths between
8 and 17 amino acids, which are the most frequently found in human antibodies, were all present in the library. The
number of sequenced clones was too small to analyze the frequency of the amino acids found in the CDR3 loops. Except
for some contamination with the original scFv 13R4 sequence, no CDR3 sequence was found twice in the library.
Expression of scFvs in the cell
[0124] Because of the novel use of the CAM selection step, the VH and VL libraries were independently optimized for
expression in the cell. Because of this optimization of the VH and VL libraries the result should be only expressed scFv
proteins. Furthermore, since only the CDR3 loops are modified between the original scFv13R4 antibody framework and
the resulting scFv libraries, most of the interface residues between the two domains are conserved between clones. It
is thus likely that any VH will assemble correctly with any VL and that the expression level of the resulting scFv will be
close to that of both clones from the VH and VL libraries selected on CAM. In other words, if a VH, with a modified H3
loop, is well expressed when fused to the VL13R4, it will be also well expressed when coupled with a VL with a modified
CDR3 loop and selected as a fusion with the VH1 3R4. This hypothesis was tested by picking random clones from the
final library and expressing them in E. coli cytoplasm and in mammalian cytosol.
[0125] DNA was prepared from the final library and the scFv genes cloned in a plasmid for cytoplasmic expression
under the control of the strong T7 promoter. It must be noted that the very high expression levels obtained under such
a strong promoter favor aggregation over soluble expression because of the high kinetics order of the aggregation
process. The stringency of this test is thus high and it could be possible to increase the soluble versus insoluble ratio
by using a weaker promoter. Twenty clones were tested in E. coli and 19 of them showed at least some soluble expression
in the cytoplasm (Figure 3). One-fourth of the clones (5/20; clones 3, 10, 11, 16, 19) were expressed at very high levels
since the scFvs were clearly visible on a Coomassie stained gel. To obtain a more global view of the soluble expression
levels in E. coli, the library was cloned in front of the GFPuv gene under the control of the T7 promoter. If the scFv is
soluble and expressed in the cytoplasm, this should result in green fluorescent protein (GFP) activity that can be directly
monitored on an UV transilluminator. About 1000 clones were tested for the presence of detectable GFP activity and
approximately 60% exhibited a GFP+ phenotype, which again indicated that most of the scFv clones from the final library
were correctly expressed in E. coli cytoplasm. These two tests demonstrated that the novel method of constructing an
scFv library as described above was very successful in generating cytoplasmically expressed scFvs in E. coli.
[0126] Next, the expression of the library in mammalian cells was tested. Fifteen scFvs were cloned in a mammalian
expression vector as fusions with the EGFP gene and under the control of the SV40 early promoter, then transfected
in HeLa cells. Typical results are shown in Figure 4. Three clones were expressed at a high soluble level, comparable
to that of the parental scFv13R4 (clone 15), 10 scFvs were found to be mainly soluble but some aggregated material
was still present in the cell (clones 33 and 36), and 2 clones accumulated essentially as cytoplasmic aggregates (clone
24), as observed with the hybridoma-derived anti-oncoprotein E6 scFv 1F4 (Figure 4). In conclusion, thirteen out of the
fifteen scFvs tested were expressed as soluble proteins that could be easily detected in the cytoplasm and in the nucleus
of the transfected cells.
[0127] Together, these results showed that more than 85% of the clones from the final library expressed soluble scFv
in E. coli (16/20) and mammalian cytoplasm (13/15), while about 20% of them expressed scFv at a very high level (5/20
in E. coli and 3/15 in eukaryotic cells). Overall, most of the clones were well expressed under the reducing conditions
of the bacterial and eukaryotic cytoplasm. This is a great improvement over results previously obtained with non-optimized
scFv libraries.
Selection of binders
[0128] As shown above, the library contains a very high proportion of expressed clones. The next step was selecting
antibodies from the library against particular proteins. Thus, the phage display library was used to select for binders
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against five different antigens using purified proteins adsorbed on microtiter plates. Three rounds of selection were
performed, and the eluted phages were tested by ELISA against the immobilized antigens. In all the cases a positive
signal was obtained after a single round of selection. This signal increased strongly after two rounds and did not increase
further during the third round of selection. This very fast selection process was presumably due both to the focused
library itself, which contains only expressed scFvs resulting in a low background, and to the use of a trypsin sensitive
helper phage that further decreased the background level.
[0129] To characterize the selection process, 60 clones were selected from the three selection rounds against GST:Syk
fusion. These clones were used to prepare monoclonal phages, which were then tested for binding to the antigen by
ELISA. Figure 7 shows the distribution of the ELISA values obtained for each selection round. The distribution was
normal with a strong homogeneity of the signal in each round of selection since more than half of the clones showed an
ELISA signal within 0.1 of the peak value. During the selection process the peak signal increased from 0.4-0.5 after a
single round to 0.9 after round 2 and 1.0 after round 3, in good correlation with the results obtained with the polyclonal
phages. Moreover, after a single round of selection nearly 100% of the clones already recognized the antigen. This
showed that using the optimized library in combination with a trypsin-sensitive helper phage results in almost a total
absence of background during the selection process.
[0130] Next tested was whether the library contained clones expressing soluble scFvs in the periplasm. The non-
suppressive HB2151 strain was infected with the phages eluted after the third round of selection against tubulin, GST:Syk
and the core histones. Periplasmic extracts were prepared and tested for binding activity by ELISA. In the three cases,
12-20% of the clones gave a strong signal with absorbance values higher than 0.5 (10 times the background), and about
30% were clearly positive with an absorbance value higher than 0.1 (twice the background). These results compared
favorably with those reported with other scfv libraries, underlining again the high proportion of well-expressed clones
present in the library. In addition, this showed that the CAM-selection approach selected efficiently for constructs without
stop codons present in the oligonucleotides. This is indeed of premium importance to isolate soluble scFvs from phage-
displayed libraries since amber stop codons in CDRs are frequently selected during panning of synthetic and semi-
synthetic libraries.
[0131] In both the previous characterizations, the scFvs were expressed under oxidizing conditions in E. coli periplasm,
either as scFv-pIII fusion or as soluble protein. In addition, panning was done on phage, again under oxidizing conditions.
To test whether the scFvs were indeed also expressed in the cytoplasm, the same pool of clones (Round 3) was subcloned
in a cytoplasmic expression vector under the control of the strong T7 promoter. For each antigen, ninety-five clones
were tested by ELISA for binding to their respective antigen. In each case, the number of positive clones was comparable
or even better than in the periplasmic screen. For instance, in the case of GST: Syk, 80% of the tested clones were
positive after three rounds of selection. This demonstrated that the periplasmic selection step did not decrease the
proportion of soluble scFvs in the cytoplasm. Furthermore, when using the optimized library as described above it is not
necessary to directly select within the cytoplasm to avoid introducing a bias during the selection.
[0132] Individual clones from the 2nd and the 3rd round of selection against tubulin were sequenced. Sequences are
shown in Table 3.
Table 3
Sequences of some anti-tubulin scfvs
VH CDR3 VL CDR3
Name Sequence length Sequence length frequencya yieldb WBc IFd
Round 2
SSITIFGGGMDV HSREVHRTF
C12C (SEQ ID NO: 34) 12 (SEQ ID NO: 35) 9 1/5 19
SGGNTFDY QQYYRKPWT
E12C (SEQ ID NO: 36) 8 (SEQ ID NO: 37) 9 1/5 53
F1C GNADGGENWELFDK 14 QLYQNTLWT 9 2/5 52
(SEQ ID NO: 38) (SEQ ID NO: 39)
SSITIFGGGMDV QQNWTSPLS
H6C (SEQ ID NO: 40) 12 (SEQ ID NO: 41) 9 1/5 nd
Round 3
RGRDY QQYNTSPFS
2C1C (SEQ ID NO: 42) 5 (SEQ ID NO: 43) 9 1/6 8.6 + -
GRNVLNY QQNSSSPRFT
2E11C (SEQ ID NO: 44) 7 (SEQ ID NO: 45) 10 2/6 8.7 + -
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[0133] In all cases, the clones sequenced were those giving the best signal in the ELISA performed with cytoplasmically
expressed scFvs. Most of the clones were different since only one clone from the 2nd round and one from the 3rd round
were found twice. This demonstrated that a high diversity is still present after 3 rounds of selection. Eight of the anti-
tubulin scFvs were purified by affinity chromatography from the cytoplasm. In all cases, more than 8 mg of scFv was
purified from one liter of cells grown in a flask (OD600 = 5), and some scFvs were expressed at a level per cell comparable
to the exceptionally high expression level reported for an anti-HER2 in E. coli periplasm.
Functionality of scFvs as intrabodies
[0134] To determine if the isolated scFvs were able to bind to their target in vivo, the anti-histone scFvs expressed in
human cells was characterized. The third round of selection was cloned in vector p513-EGFP and ten randomly chosen
clones were transfected in HeLa cells. Typical results of the cells expressing the scFv-EGFP fusions and observed by
fluorescence microscopy are shown in Figure 6. One scFv was expressed as cytoplasmic aggregates. Four scFvs were
expressed as soluble cytoplasmic proteins, as judged by the homogeneous staining of the cells, at a level comparable
to that of the scFv13R4. Finally, the expression of three scFvs gave rise to a stronger staining of the nucleus (Figure 6,
clone 2) and two scFvs were exclusively localized in the nucleus (Figure 6, clones 5 and 10). Since these scFvs-EGFP
fusion proteins were expressed in the cytoplasm of the cell and did not contain a nuclear localization signal, this suggested
that they were able to interact in vivo with the histones and were thus active inside the cell. This analysis showed that
about half of the clones present after the third round of selection against core histones were able to bind to their nuclear
target in vivo. This was confirmed in vitro by western and dot blot with purified scFv. In addition, sequencing of these
clones showed that they contained different heavy and light chain CDR3 regions.
In vitro characteriza*tion of anti-tubulin scFvs
[0135] To demonstrate the activity of the anti-tubulin scFv under the reducing conditions in the cell cytoplasm, the
scFvs were extracted in the presence of a reducing agent and compared the ELISA signal with that obtained with the
scFvs extracted under oxidizing conditions. As shown in Figure 7, the five scFvs tested gave the same ELISA signal
under both conditions, demonstrating that the scFVs retain full activity under reducing conditions even in the absence
of disulfide bond formation. The five scFvs were able to recognize unfolded tubulin by western blot in brain extracts and
the native protein in a competition ELISA. The ability of the five scFvs to interact with microtubules in cells was tested
by IF. Clones 2F12C and 2G4C revealed the microtubule network in cells.
[0136] Figure 8 illustrates the utility of the library as a source for both in vitro and in vivo proteomic studies: HeLa cells
were transfected with the anti-histones clone 5 fused to a Red-GFP, and he microtubule network was revealed by IF
using the 2F12C scFv.
[0137] Altogether our results show that the library described in this report is highly diverse and functional and allows
fast and easy isolation of in vivo active fully human intrabodies.
(continued)
Round 3
GRRALGN QQYNTSPFS
2F12C (SEQ ID NO: 46) 7 (SEQ ID NO: 47) 9 1/6 45 + +
GRRALGN LTWSMRSAI
2G4C (SEQ ID NO: 48) 7 (SEQ ID NO: 49) 9 1/6 15 + +
GRRALGN LTTENSVYRLV
2G9C (SEQ ID NO: 50) 7 (SEQ ID NO: 51) 11 1/6 50 + -
Sequences of the CDR3s of the best positive clones in an ELISA using cytoplasmically expressed scFv from the 2nd
(5 clones) and the 3rd (6 clones) round of selection (Table 3). a Frequency of apparition of the scFv among sequenced
clones of the same round. bYield: mg of scFv purified from 1 liter of cells grown in a flask (OD600 = 5). cWB: detection
of tubulin in brain extracts by Western blot. d IF: + means that the scFv is able to reveal microtubule network by
Immunofluorescence (Fig. 8). The sequences of the clones 2C1C, 2E11C, 2F12C, 2G4C and 2G9C have been
submitted to the EMBL database and their accession numbers are respectively AM886280, AM886281, AM886282,
AM886283 and AM886284.
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Claims
1. An antibody library comprising at least about 106 unique scFv antibody clones, wherein each unique scFv antibody
clone encodes a unique scFv antibody comprising at least one of a unique CDR3 VH sequence and a unique CDR3
VL sequence, and wherein the unique scFv antibody clones encode a framework sequence identical to a framework
sequence encoded by an scFv13R4 antibody clone of SEQ ID NO: 32.
2. The antibody library of claim 1, wherein the unique scFv antibody clones encode scFv antibodies comprising a
unique CDR3 VH sequence.
3. The antibody library of claim 1, wherein the unique scFv antibody clones encode scFv antibodies comprising a
unique CDR3 VL sequence.
4. The antibody library of claim 1, wherein the unique scFv antibody clones encode scFv antibodies comprising a
unique CDR3 VH sequence and a unique CDR3 VL sequence.
5. A method for preparing an scFv antibody library enriched for scFv antibody clones that can be expressed within a
cell, comprising:
a) providing a first collection of scFv antibody clones, wherein the first collection comprises clones comprising
a unique sequence within a CDR3 loop of VH, wherein the first collection has been enriched for scFv antibody
clones that contain a VL sequence identical to the VL sequence of an scFv13R4 antibody clone of SEQ ID IVO: 33;
b) providing a second collection of scFv antibody clones, wherein the second collection comprises clones
comprising a unique sequence within a CDR3 loop of VL, wherein the second collection has been enriched for
scFv antibody clones that contain a VH sequence identical to the VH sequence of an scFv13R4 antibody clone
of SEQ ID NO: 33;
c) joining VH domains from scFv antibody clones of the first collection with VL domains from scFv antibody
clones of the second collection to obtain a third collection of scFv antibody clones, wherein the third collection
contains scFv antibody clones comprising a unique sequence within the CDR3 loop of VH and a unique sequence
within the CDR3 loop of VL,
thereby preparing the scFv antibody library enriched for scFv antibody clones that can be expressed within a cell.
6. The method of claim 5, wherein the first collection comprises scFv antibody clones that comprise identical CDR1
and CDR2 sequences in the VH domain and wherein the second collection comprises scFv antibody clones that
comprise identical CDR1 and CDR2 sequences in the VL domain.
7. An antibody library produced by the method of claim 5.
8. A method for constructing an antibody library comprising:
a) selecting the framework of an scFv13R4 antibody clone of SEQ ID NO: 33 as an scFv antibody framework;
b) introducing sequence diversity into a VH CDR3 region of the scFv antibody framework to generate a first
library comprising scFv antibody clones comprising a unique VH CDR3 region;
c) introducing sequence diversity into a VL CDR3 region of the scFv antibody framework to generate a second
library comprising scFv antibody clones comprising a unique VL CDR3 region;
d) removing, from the first library, clones that do not detectably express scFv antibody;
e) removing, from the second library, clones that do not detectably express scFv antibody; and
f) recombining the first and second libraries to generate a final library comprising scFv antibody clones comprising
a unique VH CDR3 region and a unique VL CDR3 region;
thereby constructing the antibody library.
Patentansprüche
1. Antikörperbank, umfassend mindestens etwa 106 nur einmal vorkommende scFv-Antikörperklone, wobei jeder nur
einmal vorkommende scFv-Antikörperklon einen nur einmal vorkommenden scFv-Antikörper kodiert, der mindestens
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eine aus einer nur einmal vorkommenden CDR3-VH-Sequenz und einer nur einmal vorkommenden CDR3-VL-
Sequenz umfasst, und wobei die nur einmal vorkommenden scFv-Antikörperklone eine Rahmensequenz kodieren,
die mit einer durch einen scFv13R4-Antikörperklon der SEQ ID NO: 32 kodierten Rahmensequenz identisch ist.
2. Antikörperbank nach Anspruch 1, wobei die nur einmal vorkommenden scFv-Antikörperklone scFv-Antikörper ko-
dieren, die eine nur einmal vorkommende CDR3-VH-Sequenz umfassen.
3. Antikörperbank nach Anspruch 1, wobei die nur einmal vorkommenden scFv-Antikörperklone scFv-Antikörper ko-
dieren, die eine nur einmal vorkommende CDR3-VL-Sequenz umfassen.
4. Antikörperbank nach Anspruch 1, wobei die nur einmal vorkommenden scFv-Antikörperklone scFv-Antikörper ko-
dieren, die eine nur einmal vorkommende CDR3-VH-Sequenz und eine nur einmal vorkommende CDR3-VL-Se-
quenz umfassen.
5. Verfahren zum Herstellen einer für scFv-Antikörperklone, die in einer Zelle exprimiert werden können, angereicherten
scFv-Antikörperbank, umfassend:
(a) Bereitstellen einer ersten Sammlung von scFv-Antikörperklonen, wobei die erste Sammlung Klone umfasst,
die eine nur einmal vorkommende Sequenz in einem CDR3-Loop von VH umfassen, wobei die erste Sammlung
für scFv-Antikörperklone, die eine mit der VL-Sequenz eines scFv13R4-Antikörperklons der SEQ ID NO: 33
identische VL-Sequenz enthalten, angereichert worden ist;
(b) Bereitstellen einer zweiten Sammlung von scFv-Antikörperklonen, wobei die zweite Sammlung Klone um-
fasst, die eine nur einmal vorkommende Sequenz in einem CDR3-Loop von VL umfassen, wobei die zweite
Sammlung für scFv-Antikörperklone, die eine mit der VH-Sequenz eines scFv13R4-Antikörperklons der SEQ
ID NO: 33 identische VH-Sequenz enthalten, angereichert worden ist;
(c) Verknüpfen von VH-Domänen von scFv-Antikörperklonen der ersten Sammlung mit VL-Domänen von scFv-
Antikörperklonen der zweiten Sammlung, um eine dritte Sammlung von scFv-Antikörperklonen zu erhalten,
wobei die dritte Sammlung scFv-Antikörperklone enthält, die eine nur einmal vorkommende Sequenz im CDR3-
Loop von VH und eine nur einmal vorkommende Sequenz im CDR3-Loop von VL umfassen,
wodurch die für scFv-Antikörperklone, die in einer Zelle exprimiert werden können, angereicherte scFv-Antikörper-
bank hergestellt wird.
6. Verfahren nach Anspruch 5, wobei die erste Sammlung scFv-Antikörperklone umfasst, die identische CDR1- und
CDR2-Sequenzen in der VH-Domäne umfassen, und wobei die zweite Sammlung scFv-Antikörperklone umfasst,
die identische CDR1- und CDR2-Sequenzen in der VL-Domäne umfassen.
7. Antikörperbank, hergestellt durch das Verfahren nach Anspruch 5.
8. Verfahren zum Konstruieren einer Antikörperbank, umfassend:
(a) Auswählen des Rahmens eines scFv13R4-Antikörperklons der SEQ ID NO: 33 als scFv-Antikörper-Rahmen;
(b) Einführen von Sequenzdiversität in eine VH-CDR3-Region des scFv-Antikörper-Rahmens, um eine erste
Bank zu erzeugen, die scFv-Antikörperklone, umfassend eine nur einmal vorkommende VH-CDR3-Region,
umfasst;
(c) Einführen von Sequenzdiversität in eine VL-CDR3-Region des scFv-Antikörper-Rahmens, um eine zweite
Bank zu erzeugen, die scFv-Antikörperklone, umfassend eine nur einmal vorkommende VL-CDR3-Region,
umfasst;
(d) Entfernen von Klonen aus der ersten Bank, die einen scFv-Antikörper nicht nachweisbar exprimieren;
(e) Entfernen von Klonen aus der zweiten Bank, die einen scFv-Antikörper nicht nachweisbar exprimieren, und
(f) Rekombinieren der ersten und zweiten Bank, um eine endgültige Bank zu erzeugen, die scFv-Antikörperklone,
umfassend eine nur einmal vorkommende VH-CDR3-Region und eine nur einmal vorkommende VL-CDR3-
Region, umfasst;
wodurch die Antikörperbank konstruiert wird.
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Revendications
1. Bibliothèque d’anticorps comprenant au moins environ 106 clones d’anticorps scFv unique, chaque clone d’anticorps
scFv unique codant un anticorps scFv unique comprenant au moins une séquence parmi une séquence VH CDR3
unique et une séquence VL CDR3.unique, et dans lequel les clones d’anticorps scFv unique codent une séquence
d’ossature identique à une séquence d’ossature codée par un clone d’anticorps scFv13R4 de SEQ ID NO : 32.
2. Bibliothèque d’anticorps selon la revendication 1, dans laquelle les clones d’anticorps scFv unique comprennent
une séquence VH CDR3 unique.
3. Bibliothèque d’anticorps selon la revendication 1, dans laquelle les clones d’anticorps scFv unique comprennent
une séquence VL CDR3 unique.
4. Bibliothèque d’ anticorps selon la revendication 1, dans laquelle les clones d’anticorps scFv unique codent des
anticorps scFv comprenant une séquence VH CDR3 unique et une séquence VL CDR3 unique.
5. Procédé de préparation d’une bibliothèque d’anticorps scFv enrichis en clones d’anticorps scFv qui peuvent exprimer
dans une cellule, consistant à :
a) fournir une première collection de clones d’anticorps scFv, la première collection comprenant des clones
comprenant une séquence unique dans une boucle de VH de CDR3, la première collection ayant été enrichie
en clones d’anticorps scFv qui contiennent une séquence VL identique à la séquence V1 d’un clone d’ anticorps
scFv13R4 de SEQ ID NO : 33 ;
b) fournir une deuxième collection de clones d’anticorps scFv, la seconde collection comprenant des clones
comprenant une séquence unique dans une boucle de VL de CDR3, la deuxième collection ayant été enrichie
en clones d’anticorps scFv qui contiennent une séquence VH identique à la séquence VH d’un clone d’anticorps
scFv13R4 de SEQ ID NO : 33 ;
c) relier les domaines VH. provenant des clones d’anticorps scFv de la première collection à des domaines VL
provenant de clones d’anticorps scFv de la seconde collection pour obtenir une troisième collection de clones
d’anticorps scFv, la troisième collection contenant des clones anticorps scFv comprenant une séquence unique
dans la boucle de VH de CDR3 et une séquence unique dans la boucle de VL de CDR3, en préparant ainsi la
bibliothèque d’anticorps scFv enrichie en clones d’anticorps scFv qui peuvent exprimer dans une cellule.
6. Procédé selon la revendication 5, dans lequel la première collection comprend des clones d’anticorps scFv qui
comprennent des séquences CDR1 et CDR2 identiques dans le domaine VH, et dans lequel la deuxième collection
comprend des clones d’ anticorps scFv qui comprennent des séquences CDR1 et CDR2 identiques dans le domaine
VL.
7. Bibliothèque d’anticorps produite par le procédé selon la revendication 5.
8. Procédé de construction d’une bibliothèque d’anticorps, consistant à :
a) sélectionner l’ossature d’un clone d’anticorps scFv13R4 de SEQ ID NO : 33 en tant que’ossature d’anticorps
scFv;
b) introduire une diversité de séquences dans une région VH CDR3 de l’ossature d’anticorps scFv pour produire
une première bibliothèque comprenant des clones d’anticorps scFv comprenant une région VH CDR3 unique ;
c) introduire une diversité de séquences dans une région VL CDR3 de l’ossature d’anticorps scFv pour produire
une deuxième bibliothèque comprenant des clones d’anticorps scFv comprenant une région VL CDR3 unique;
d) enlever, à partir de la première bibliothèque, les clones qui n’ont pas exprimé de manière détectable un
anticorps scFv ;
e) enlever, de la deuxième bibliothèque, des clones qui n’ont pas exprimé de manière détectable un anticorps
scFv; et
f) recombiner les premières et deuxième bibliothèques pour produire une bibliothèque finale comprenant des
clones d’anticorps scFv comprenant une région VH CDR3 unique et une région VL CDR3 unique,
construisant ainsi la bibliothèque d’anticorps.
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